{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T19:37:31Z","timestamp":1791229051829,"version":"4.1.0"},"reference-count":25,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100002429","name":"Amgen Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinical-genitourinary-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Genitourinary Cancer"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.clgc.2026.102529","type":"journal-article","created":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T16:37:14Z","timestamp":1772728634000},"page":"102529","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Survival Outcomes of Cabazitaxel or Subsequent Androgen Receptor Pathway Inhibitor (ARPI) in Post-Docetaxel\/ARPI Metastatic Castration-Resistant Prostate Cancer"],"prefix":"10.1016","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8890-2951","authenticated-orcid":false,"given":"Pedro C.","family":"Barata","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren","family":"Green","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8598-275X","authenticated-orcid":false,"given":"Yunji","family":"Hwang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.clgc.2026.102529_bib0001","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"10.1016\/j.clgc.2026.102529_bib0002","first-page":"12","article-title":"Cancer statistics, 2024","volume":"74","author":"Siegel","year":"2024","journal-title":"CA Cancer J Clin"},{"issue":"4","key":"10.1016\/j.clgc.2026.102529_bib0003","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1007\/s11523-022-00899-6","article-title":"Pattern of clinical progression until metastatic castration-resistant prostate cancer: an epidemiological study from the European Prostate Cancer Registry","volume":"17","author":"Verry","year":"2022","journal-title":"Target Oncol"},{"key":"10.1016\/j.clgc.2026.102529_bib0004","doi-asserted-by":"crossref","first-page":"100962","DOI":"10.1016\/j.drup.2023.100962","article-title":"Current therapy and drug resistance in metastatic castration-resistant prostate cancer","volume":"68","author":"Cai","year":"2023","journal-title":"Drug Resist Updat"},{"key":"10.1016\/j.clgc.2026.102529_bib0005","first-page":"339","article-title":"Treatment landscape for patients with castration-resistant prostate cancer: patient selection and unmet clinical needs","volume":"14","author":"Turco","year":"2022","journal-title":"Res Rep Urol"},{"issue":"7","key":"10.1016\/j.clgc.2026.102529_bib0006","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1007\/s11864-024-01215-2","article-title":"Metastatic castration-resistant prostate cancer: advances in treatment and symptom management","volume":"25","author":"Kulasegaran","year":"2024","journal-title":"Curr Treat Options Oncol"},{"issue":"7","key":"10.1016\/j.clgc.2026.102529_bib0007","doi-asserted-by":"crossref","first-page":"3901","DOI":"10.21873\/anticanres.13541","article-title":"Abiraterone acetate and enzalutamide: similar efficacy in treating post docetaxel metastatic castration-resistant prostate cancer: single center experience","volume":"39","author":"Chang","year":"2019","journal-title":"Anticancer Res,"},{"issue":"2","key":"10.1016\/j.clgc.2026.102529_bib0008","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1038\/s41391-023-00725-8","article-title":"Real-world treatment patterns and overall survival among men with metastatic castration-resistant prostate cancer (mCRPC) in the US Medicare population","volume":"27","author":"Freedland","year":"2024","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"5","key":"10.1016\/j.clgc.2026.102529_bib0009","doi-asserted-by":"crossref","first-page":"496.e1","DOI":"10.1016\/j.clgc.2022.04.009","article-title":"Real-world cabazitaxel use and outcomes in metastatic castrate-resistant prostate cancer: the impact of response to first ARPI","volume":"20","author":"Watson","year":"2022","journal-title":"Clin Genitourin Cancer"},{"issue":"1","key":"10.1016\/j.clgc.2026.102529_bib0010","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1186\/s12885-023-10998-w","article-title":"Real-world effectiveness of third-line cabazitaxel in patients with metastatic castration-resistant prostate cancer: CARD-like analysis of data from a post-marketing surveillance in Japan","volume":"23","author":"Matsuyama","year":"2023","journal-title":"BMC Cancer"},{"key":"10.1016\/j.clgc.2026.102529_bib0011","doi-asserted-by":"crossref","first-page":"1108937","DOI":"10.3389\/fonc.2023.1108937","article-title":"Real-life data of abiraterone acetate and enzalutamide treatment in post-chemotherapy metastatic castration-resistant prostate cancer in Poland","volume":"13","author":"Sigorski","year":"2023","journal-title":"Front Oncol"},{"issue":"1","key":"10.1016\/j.clgc.2026.102529_bib0012","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1186\/s12885-019-5974-9","article-title":"Efficacy and safety of abiraterone acetate plus prednisone vs. cabazitaxel as a subsequent treatment after first-line docetaxel in metastatic castration-resistant prostate cancer: results from a prospective observational study (CAPRO)","volume":"19","author":"Puente","year":"2019","journal-title":"BMC Cancer"},{"issue":"5","key":"10.1016\/j.clgc.2026.102529_bib0013","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A new method of classifying prognostic comorbidity in longitudinal studies: development and validation","volume":"40","author":"Charlson","year":"1987","journal-title":"J Chronic Dis"},{"issue":"6","key":"10.1016\/j.clgc.2026.102529_bib0014","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/0895-4356(92)90133-8","article-title":"Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases","volume":"45","author":"Deyo","year":"1992","journal-title":"J Clin Epidemiol"},{"issue":"3","key":"10.1016\/j.clgc.2026.102529_bib0015","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1007\/s11523-021-00807-4","article-title":"Real-world safety and efficacy outcomes with abiraterone acetate plus prednisone or prednisolone as the first- or second-line treatment for metastatic castration-resistant prostate cancer: data from the Prostate Cancer Registry","volume":"16","author":"Bjartell","year":"2021","journal-title":"Target Oncol"},{"issue":"8","key":"10.1016\/j.clgc.2026.102529_bib0016","doi-asserted-by":"crossref","first-page":"4520","DOI":"10.1007\/s12325-021-01823-6","article-title":"Real-world treatment patterns and overall survival of patients with metastatic castration-resistant prostate cancer in the US prior to PARP inhibitors","volume":"38","author":"Shore","year":"2021","journal-title":"Adv Ther"},{"issue":"1","key":"10.1016\/j.clgc.2026.102529_bib0017","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/s41391-021-00487-1","article-title":"Real-world evidence of patients with metastatic castration-resistant prostate cancer treated with cabazitaxel: comparison with the randomized clinical study CARD","volume":"26","author":"de Wit","year":"2023","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"4","key":"10.1016\/j.clgc.2026.102529_bib0018","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1111\/bju.15542","article-title":"Safety and survival of docetaxel and cabazitaxel in metastatic castration-resistant prostate cancer","volume":"129","author":"Kreis","year":"2022","journal-title":"BJU Int"},{"key":"10.1016\/j.clgc.2026.102529_bib0019","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.ejca.2019.05.007","article-title":"Plasma AR status and cabazitaxel in heavily treated metastatic castration-resistant prostate cancer","volume":"116","author":"Conteduca","year":"2019","journal-title":"Eur J Cancer"},{"issue":"26","key":"10.1016\/j.clgc.2026.102529_bib0020","doi-asserted-by":"crossref","first-page":"2506","DOI":"10.1056\/NEJMoa1911206","article-title":"Cabazitaxel versus abiraterone or enzalutamide in metastatic prostate cancer","volume":"381","author":"de Wit","year":"2019","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.clgc.2026.102529_bib0021","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/j.eururo.2021.06.021","article-title":"Efficacy and safety of cabazitaxel versus abiraterone or enzalutamide in older patients with metastatic castration-resistant prostate cancer in the CARD study","volume":"80","author":"Sternberg","year":"2021","journal-title":"Eur Urol"},{"issue":"8","key":"10.1016\/j.clgc.2026.102529_bib0022","doi-asserted-by":"crossref","first-page":"3465","DOI":"10.1007\/s12094-025-03851-y","article-title":"Cabazitaxel versus abiraterone or enzalutamide for metastatic castration-resistant prostate cancer following docetaxel failure: a systematic review and meta-analysis","volume":"27","author":"da Silva","year":"2025","journal-title":"Clin Transl Oncol"},{"issue":"4","key":"10.1016\/j.clgc.2026.102529_bib0023","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.urolonc.2022.06.018","article-title":"Sequencing impact and prognostic factors in metastatic castration-resistant prostate cancer patients treated with cabazitaxel: a systematic review and meta-analysis","volume":"41","author":"Yanagisawa","year":"2023","journal-title":"Urol Oncol"},{"issue":"4","key":"10.1016\/j.clgc.2026.102529_bib0024","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/j.clgc.2017.01.019","article-title":"Which factors predict overall survival in patients with metastatic castration-resistant prostate cancer treated with abiraterone acetate post-docetaxel?","volume":"15","author":"Van Praet","year":"2017","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.clgc.2026.102529_bib0025","article-title":"Improving real-world mortality data quality in oncology research: augmenting electronic medical records with obituary, Social Security Death Index, and commercial claims data","volume":"7","author":"Shao","year":"2023","journal-title":"JCO Clin Cancer Inform"}],"container-title":["Clinical Genitourinary Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767326000297?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767326000297?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T14:29:26Z","timestamp":1778941766000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1558767326000297"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":25,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S1558767326000297"],"URL":"https:\/\/doi.org\/10.1016\/j.clgc.2026.102529","relation":{},"ISSN":["1558-7673"],"issn-type":[{"value":"1558-7673","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Survival Outcomes of Cabazitaxel or Subsequent Androgen Receptor Pathway Inhibitor (ARPI) in Post-Docetaxel\/ARPI Metastatic Castration-Resistant Prostate Cancer","name":"articletitle","label":"Article Title"},{"value":"Clinical Genitourinary Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clgc.2026.102529","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102529"}}